A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

NCT05409482 · clinicaltrials.gov ↗
RECRUITING
Status
300
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Collaborators